Small cell lung cancer - 20240178

The main objective of the study is to compare the efficacy of tarlatamab in combination with durvalumab, carboplatin and etoposide to the combination of durvalumab, carboplatin and etoposide on prolonging overall survival (OS).

ClinicalTrials.gov Link: https://clinicaltrials.gov/study/NCT07005128?viewType=Card&id=20240178&rank=1

Locations: Hartford Hospital, Hartford HealthCare Medical Group - Manchester, Hartford HealthCare Cancer Institute - Avon, Hartford HealthCare Cancer Institute at The Hospital of Central Connecticut, MidState Medical Center

Contact: Siobhan Reilly: Siobhan.reilly@hhchealth.org